Update of newly‐recognized salivary gland neoplasms: molecular and immunohistochemical findings and clinical importance

With the advancement of molecular testing and the routine use of immunohistochemical stains, salivary gland tumours previously categorized as adenoma or adenocarcinoma, not otherwise specified, are being reclassified with distinct diagnoses. Newly recognized benign entities include: sclerosing polycystic adenoma, keratocystoma, intercalated duct hyperplasia and adenoma, and striated duct adenoma. Newly recognized malignant salivary gland tumours include: microsecretory adenocarcinoma, sclerosing microcytic adenocarcinoma, and mucinous adenocarcinoma. Additionally, rare subtypes of mucoepidermoid carcinoma have been described, including Warthin‐like and oncocytic. Understanding of intraductal carcinoma continues to evolve. Correctly distinguishing these lesions from mimickers can be crucial for appropriate patient care and prognostication, as well as future conceptualization of salivary disease. Molecular, immunohistochemical, and clinical understanding of salivary gland lesions has advanced in recent years, yielding reclassification and a shift in nomenclature of benign and malignant neoplasms. Pathogenic understanding, clinical treatment, and patient prognostication will improve with increasing knowledge of these diverse entities.